HC Wainwright Has Positive Estimate for NRXP FY2026 Earnings

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Investment analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for NRx Pharmaceuticals in a research note issued on Tuesday, March 3rd. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.13 per share for the year, up from their prior forecast of $0.12. HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.75) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q4 2026 earnings at $0.06 EPS, FY2027 earnings at $1.23 EPS, FY2028 earnings at $3.18 EPS and FY2029 earnings at $5.06 EPS.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research note on Monday, December 29th. BTIG Research reiterated a “buy” rating and issued a $25.00 price objective on shares of NRx Pharmaceuticals in a report on Wednesday, February 18th. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. Ascendiant Capital Markets reaffirmed a “buy” rating and issued a $48.00 price target (up from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. Finally, Zacks Research raised shares of NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $38.00.

NRx Pharmaceuticals Trading Up 3.9%

Shares of NASDAQ:NRXP opened at $1.87 on Thursday. NRx Pharmaceuticals has a 1-year low of $1.58 and a 1-year high of $3.84. The stock has a market capitalization of $59.60 million, a P/E ratio of -0.80 and a beta of 1.97. The business has a 50-day moving average price of $2.11 and a two-hundred day moving average price of $2.51.

Institutional Investors Weigh In On NRx Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Ethos Financial Group LLC acquired a new position in NRx Pharmaceuticals in the 3rd quarter worth $39,000. Sjbenen Advisory LLC acquired a new position in shares of NRx Pharmaceuticals during the fourth quarter worth about $41,000. One Wealth Management Investment & Advisory Services LLC grew its holdings in shares of NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after buying an additional 12,950 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in NRx Pharmaceuticals in the 4th quarter valued at approximately $107,000. Finally, Two Sigma Investments LP lifted its stake in NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after acquiring an additional 20,880 shares in the last quarter. Institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals News Summary

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its price target to $45 and reiterated a “Buy”, calling for substantial long-term upside; the shop also bumped multi-year EPS forecasts (FY2026–FY2029), signaling improved earnings visibility and a bullish outlook for growth. HC Wainwright Forecasts Strong Price Appreciation for NRx Pharmaceuticals
• Neutral Sentiment: Zacks Research upgraded NRXP from “strong sell” to “hold”, a modest improvement in sell-side sentiment but short of a buy signal; this change may attract some cautious buyers but is unlikely to drive a large move by itself. Zacks upgrade coverage
• Negative Sentiment: HC Wainwright trimmed its Q3 2026 EPS estimate slightly (from $0.04 to $0.03) and the street consensus still shows NRx as unprofitable for the current full year (consensus ~ -$1.75), highlighting near-term execution/visibility risks despite the bullish long-term thesis.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.